Table 5.

Association between serum IL-6 concentrations and colorectal adenoma recurrence among intervention group participants of the PPT (n = 872)

IL-6 quartiles* (pg/mL)Adenoma recurrence (T4)
NoAdvancedHigh-riskAny
n (%)n (%)OR (95% CI)n (%)OR (95% CI)n (%)OR (95% CI)
Trial (T1,3)
    Q1: >2.80125 (57.6)15 (6.9)1.0035 (16.1)1.0092 (42.4)1.00
    Q2: 1.99-2.80127 (58.3)12 (5.5)0.79 (0.34-1.81)26 (11.9)0.71 (0.39-1.27)91 (41.7)1.01 (0.68-1.49)
    Q3: 1.47-1.98131 (60.1)16 (7.3)1.19 (0.53-2.63)26 (11.9)0.82 (0.45-1.48)87 (39.9)1.01 (0.68-1.49)
    Q4: <1.47141 (64.4)6 (2.7)0.51 (0.19-1.41)13 (5.9)0.45 (0.22-0.92)78 (35.6)0.95 (0.63-1.42)
    P-trend0.380.050.80
Change (T1,3-T0)
    Q1: >0.55123 (56.7)14 (6.5)1.0033 (15.2)1.0094 (43.3)1.00
    Q2: 0.06-0.55129 (59.2)17 (7.8)1.39 (0.63-3.06)24 (11.0)0.76 (0.42-1.41)89 (40.8)0.98 (0.66-1.45)
    Q3:-0.43-0.05131 (60.1)10 (4.6)0.83 (0.34-2.00)24 (11.0)0.79 (0.43-1.45)87 (39.9)0.98 (0.66-1.45)
    Q4: <−0.43141 (64.4)8 (3.7)0.47 (0.19-1.18)19 (8.7)0.44 (0.23-0.84)78 (35.6)0.72 (0.48-1.06)
    P-trend0.060.020.09
  • *IL-6 concentrations in quartiles (Q1-Q4) of the geometric mean values of year 1 and year 3 values [Trial (T1,3)] and of the change in IL-concentrations from baseline [Change (T1,3-T0)].

  • Multivariate OR and 95% CI models were adjusted for age tertiles (<58, 58-66, >66 y), sex, average BMI (<25, 25.0-29.9, ≥30 kg/m2), and current smoking status during the first 3 trial years.

  • The ln[ln(value + 1)]–transformed median concentrations of each quartile were used as a continuous score variable to determine the P value for trend for the IL-6 concentrations at T1,3. The median concentrations of each quartile were used to determine the P value for trend for the change in IL-6 concentrations (T1,3-T0).